The antibody was previously also licensed for use with another taxane, docetaxel. However, new data submitted to the Committee for Medicinal Products for Human Use showed that the combination of bevacizumab with docetaxel has a smaller effect on progression-free survival than previously thought, and may even reduce overall survival. Accordingly, use of this combination is no longer recommended.
The Committee concluded that the risk-benefit balance for combination use of bevacizumab with paclitaxel remains positive.
The other indications of Avastin, including non-small cell lung cancer, colorectal cancer and renal cell carcinoma, are unaffected by the change.
Further information: Roche